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        The complement system is essential for an eff  ec-
tive immune response against invading pathogens. 
Conserved microbial sugars or microbe-bound 
antibodies initiate a cascade of protein  –  protein 
interactions and proteolytic steps, which result in 
the formation of target-bound convertases that 
cleave C3 and C5 into biologically important 
complement fragments (  1, 2  ). The small frag-
ments C3a and C5a serve as potent proinfl  am-
matory mediators that attract phagocytes to the 
site of infection and activate them. Deposition 
of large C3 cleavage products (C3b and iC3b) 
on microbial surfaces greatly enhances bacterial 
uptake by phagocytic cells (  3, 4  ). Furthermore, 
complement can directly kill gram-negative 
bacteria via formation of a membrane attack 
com  plex (MAC), composed of C5b, C6, C7, C8, 
and multiple C9, that inserts into target mem-
branes and promotes osmotic lysis (  5  ). Next to 
its benefi  cial role in host defense, complement 
also promotes many unwanted infl  ammatory 
re  actions in pathological conditions such as auto-
immune diseases (  6  ), allergies (  7  ), allograft/
xenograft rejection (  8  ), and systemic infl  amma-
tion during sepsis (  9  ). 
  Complement activation occurs via three dif-
ferent recognition pathways that converge at the 
level of C3 by forming C3-cleaving proteases, 
the C3 convertases (  10  ). Activation of the clas-
sical pathway (CP) and lectin pathway (LP) re-
sults in the cleavage of C4 and C2 by C1s or 
mannose-binding lectin  –  associated serine pro-
tease 2, generating a C4b2a complex, the C3 
convertase of the CP/LP (  11, 12  ). The alterna-
tive pathway (AP) is initiated by formation of 
either spontaneously hydrolyzed C3 (C3  H2O  ) in 
fl  uid-phase or surface-bound C3b deposited by 
the CP/LP. Generated C3b can form a complex 
with factor B (fB) that is activated by factor D 
(fD) to generate the C3bBb complex, the C3 con-
vertase of the AP (  13  ). 
  The C3 convertases (C4b2a and C3bBb) 
are of major biological importance, as they me-
diate the release of C3a and the deposition of 
large numbers of C3b molecules onto bacterial 
surfaces. C3 convertases consist of a covalently 
surface-bound noncatalytic subunit (C4b or 
C3b), which is in complex with the catalytic 
subunit (C2a or Bb). Because of the rapid and 
irreversible dissociation of the catalytic subunits, 
convertases only have a short lifespan of 1 –  2 min. 
C3 convertases also function as precursors of 
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inhibitors acting via a novel convertase-inhibitory mechanism. 
Because complement inhibition by Efb and Ecb is not human 
specifi  c, we could for the fi  rst time demonstrate the in vivo 
potency of an   S. aureus    –  derived complement inhibitor. 
    RESULTS   
  CHIPS and SCIN homologues are part of a new IEC 
  Database analyses revealed that   S. aureus   contains three open 
reading frames (ORFs) with a high homology to SCIN, 
whereas no noteworthy homologues were found in other 
  microorganisms. We identifi  ed SCIN-B, SCIN-C, and ORF-D 
as sharing 48, 46, and 33% homology with SCIN, respectively 
(Fig. S1 A, available at http://www.jem.org/cgi/content/
full/jem.20070818/DC1). Surprisingly, we found that CHIPS 
and SCIN homologues are clustered on the genome of all se-
quenced S.   aureus   strains (  Fig. 1  ).   The cluster contains the 
gene for FLIPr (  fl r   ) or FLIPr-like (  fl l   ) in combination with the 
gene for SCIN-B (  scb  ) or SCIN-C (  scc  ). The ORF-D gene is 
outside this cluster, directly upstream of the staphylocoagulase 
precursor gene. Next to CHIPS and SCIN homologues, we 
found this cluster to harbor the genes for Efb (  efb  ) and a 33% 
homologue of Efb, which we termed Ecb (  ecb  ). Efb has dual 
functions because its N terminus binds fi  brinogen, whereas its 
C-terminal part (C3-binding domain of Efb [Efb-C]) binds 
diff  erent C3 molecules (  27  –  30  ). The homology between Efb 
and Ecb is mainly located in Efb-C (Fig. S1 B). Both the C3-
binding properties of Efb-C and the high homology with Ecb 
suggest that these molecules may play an important role in 
staphylococcal complement evasion. Furthermore, we found 
this cluster to encode a putative outer membrane protein 
(SA1002),      -hemolysin, and three exotoxin-like molecules. 
Because the exotoxins are structural homologues of staphylo-
coccal superantigens, they are referred to as staphylococcal 
superantigen  –  like 12 (SSL12), SSL13, and SSL14 (Fraser, J.D., 
personal communication) (  31  ). The borders of IEC-2 are rep-
resented by the housekeeping genes   murI   (glutamate racemase) 
and   argF   (ornithine carbamoyltransferase), as well as SA0998 
C5 convertases (  11, 14, 15  ). In response to the deposition of 
high C3b concentrations on target surfaces, C3 convertases 
switch to C5 convertases to cleave C5, initiating the release of 
C5a and the formation of the cytolytic MAC (  16  –  18  ). During 
this process, assembly of one C3b molecule on the C3 con-
vertase results in the formation of C4b-C3b or C3b-C3b di-
mers that have high affi   nities for C5. 
  In recent years, it has become evident that bacteria have 
evolved sophisticated strategies to escape complement-mediated 
immune responses.   Staphylococcus aureus   secretes several com-
plement modulators to target diff  erent steps in the complement 
cascade (  19, 20  ). Phagocyte activation by C5a is eff  ectively 
blocked by the chemotaxis inhibitory protein of   S. aureus   
(CHIPS) that binds the C5a receptor (C5aR), as well as the 
formylated peptide receptor (FPR) (  21  ). The recently described 
staphylococcal complement inhibitor (SCIN) interferes with 
all complement activation pathways by blocking C3 conver-
tases (  22  –  24  ). The CHIPS and SCIN genes are part of the fi  rst 
immune evasion cluster (IEC-1) in   S. aureus  , a bacteriophage-
localized element that also encodes staphylokinase and staphy-
lococcal enterotoxin A (  25  ). Although CHIPS and SCIN are 
promising molecules to target complement diseases, their strict 
specifi  city for human complement proteins has limited activ-
ity studies in vivo. Nevertheless, their importance as staphylo-
coccal immune modulators prompted us to seek homologous 
proteins in   S. aureus  . This led to the identifi  cation of a CHIPS 
homologue (28% amino acid homology) that blocks FPR-like 1 
receptor signaling: FPR-like 1 inhibitory protein (FLIPr) (  26  ). 
A 73% homologue of FLIPr (FLIPr-like) is also involved in 
modulation of FPRs (unpublished data). 
  In this study, we identify two SCIN homologues that 
have complement inhibitory properties similar to SCIN. In-
triguingly, the genomic location of both CHIPS and SCIN 
homologues reveals a novel second IEC in   S. aureus  , IEC-2. 
Extracellular fi  brinogen-binding protein (Efb) and its homo-
logue, extracellular complement-binding protein (Ecb), both 
located on IEC-2, are now identifi  ed as potent complement 
  Figure 1.     A new IEC in     S. aureus          .       Graphic representation of the novel IEC-2 in sequenced   S. aureus   strains. Black arrows indicate known or putative 
immune evasion molecules: Ecb (  ecb  ), FLIPr (  fl  r  ), FLIPr-like (  fl  l  ), Efb (  efb  ), SCIN-B (  scb  ), SCIN-C (  scc ),     -hemolysin  ( hla  ), SSL12 (  ssl12  ), SSL13 (  ssl13  ), and SSL14 
(  ssl14  ). Genes with unknown functions are named according to their locus number in   S. aureus   N315. All strains carry either   fl  r   (black) or   fl  l   (dark  gray) 
and   scb   (black) or   scc   (dark gray). The household genes (light gray)   murI   (glutamate racemase), SA998, SA999, and   argF   (ornithine  carbamoyltransferase) 
form the borders of IEC-2. White arrows delineate ORFs similar to bacteriophage proteins. Three transposases for insertion sequences were found: SA1006 
in N315 and Mu50, and SAR1138 in MRSA252.   S. aureus   strain RF122 represents a bovine isolate.     JEM VOL. 204, October 1, 2007 
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that SCIN-B and SCIN-C eff  ectively blocked C5a-mediated 
calcium mobilization, whereas ORF-D had no eff  ect (  Fig. 
2 A  ).   C5a responses were also inhibited by Efb-C and Ecb 
(  Fig. 2 B  ). C5a responses were not aff  ected when proteins 
were added to supernatants after opsonization. As a diff  erent 
readout for neutrophil activation, we analyzed expression of 
CD11b and CD62L. In concordance with calcium mobiliza-
tion assays, supernatants generated in the presence of SCIN-B, 
SCIN-C, Efb-C, or Ecb contained less C5a because they 
could not up- or down-regulate CD11b and CD62L, respec-
tively (  Fig. 2, C and D  ) (  33  ). Next to C5a formation, we 
studied the eff  ect of SCIN-B, SCIN-C, ORF-D, Efb-C, and 
Ecb on phagocytosis. Neutrophil uptake of FITC-labeled   
S. aureus   in the presence of human serum was strongly inhibited 
by SCIN-B and SCIN-C (  Fig. 2 E  ). In contrast, Efb-C, Ecb, 
and ORF-D did not aff  ect phagocytosis (  Fig. 2 E  ), even at 
diff  erent serum concentrations (not depicted). Because eff  ec-
tive phagocytosis of bacteria depends on the presence of op-
sonic C3 fragments (  34, 35  ), it was not surprising to fi  nd that 
Efb-C and Ecb also did not inhibit deposition of C3b/iC3b 
on   S. aureus   (  Fig. 2 F  ). Only SCIN, SCIN-B, and SCIN-C 
strongly prevented deposition of C3b/iC3b in normal human 
serum. To study whether SCIN-B, SCIN-C, Efb, and Ecb 
are produced in vivo, we analyzed the presence of antibodies 
against SCIN-B, SCIN-C, Efb-C, and Ecb in humans. We 
found that antibodies capable of recognizing each of the re-
combinant molecules are present in humans (  Fig. 2G  ). 
  In conclusion, SCIN-B and SCIN-C are effi   cient com-
plement inhibitors that prevent C5a generation, C3b/iC3b 
and SA0999 (homologues of the housekeeping genes). Of 
note, the presence of transposases and bacteriophage remnants 
suggests that this cluster has evolved through horizontal gene 
transfer (  32  ). In summary, the clustering of several known and 
potential immune evasion molecules indicates this region rep-
resents a novel second IEC in   S. aureus   (IEC-2). In this paper, 
we will investigate the immune evasive properties of four mol-
ecules on IEC-2: SCIN-B, SCIN-C, Efb, and Ecb. 
  Prevalence of SCIN and Efb homologues in   S. aureus   strains 
  PCR analyses of 84 clinical   S. aureus   strains and 6 classical lab 
strains revealed that the genes encoding SCIN-B (  scb  ), SCIN-C 
(  scc  ), and ORF-D (  orf-d  ) are carried by 47, 32, and 98% of   
S. aureus   strains, respectively. As observed for sequenced strains, 
clinical   S. aureus   strains also carry either   scb   or   scc  . The genes 
encoding Efb (  efb  ) and Ecb (  ecb  ) were found in 85 and 98% of 
  S. aureus   strains, respectively. All are secreted proteins because 
they contain a signal peptide and a signal peptide cleavage site. 
  Innate immune evasion by the SCIN homologues, 
Efb-C and Ecb 
  The recombinant SCIN homologues, Efb-C and Ecb were 
tested in several in vitro assays that mimic critical steps of 
complement-mediated immune responses against   S. aureus  . 
To analyze complement activation at the level of C5a,   S. aureus   
was initially incubated with human serum in the presence 
or absence of inhibitors. Collected supernatants were subse-
quently tested for their capacity to activate neutrophils, a re-
sponse that is completely C5a dependent (  23  ). We observed 
  Figure 2.     Innate immune evasion by four putative complement inhibitors on IEC-2. (A) SCIN-B and SCIN-C inhibit C5a production.   S. aureus   was 
incubated with 10% human serum in the presence of 10   μ  g/ml SCIN (     ), SCIN-B (  •  ), SCIN-C (     ), or ORF-D (     ). C5a formation was measured by using 
supernatants as stimuli for calcium mobilization of human neutrophils. SCIN-B and SCIN-C show a dose-dependent inhibition of C5a formation, whereas 
ORF-D had no effect. (B) Efb-C and Ecb block C5a production during opsonization. Dose-dependent inhibition of C5a-mediated neutrophil activation by 
Efb-C (     ), Ecb (  Δ  ), and SCIN (     ). (C) Supernatants that were activated in the presence of 10   μ  g/ml SCIN, SCIN-B, SCIN-C, Efb-C, or Ecb were less potent 
in up-regulating CD11b expression on neutrophils. (D) Supernatants that were activated in the presence of 10   μ  g/ml SCIN, SCIN-B, SCIN-C, Efb-C, or Ecb 
were less potent in down-regulation of CD62L expression on neutrophils. (E) SCIN (     ), SCIN-B (  •  ), and SCIN-C (     ) inhibit phagocytosis of   S. aureus   by 
human neutrophils in 10% human serum. ORF-D (     ), Efb-C (     ), and Ecb (  Δ  ) did not affect phagocytosis. (F) SCIN, SCIN-B, and SCIN-C inhibit C3b/iC3b 
deposition on the bacterial surface in 10% human serum, whereas Efb-C and Ecb do not infl  uence opsonization. (G) Antibody titers against SCIN, SCIN-B, 
SCIN-C, Efb, and Ecb in sera of 12 healthy lab volunteers. Horizontal lines represent the mean. All data represent the mean       SE of three separate experiments. 
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C4b deposition during CP or LP activation (  24  ). Because 
stabilization of inherently labile C3 convertases is a hallmark 
of SCIN activity, we examined the convertase-stabilizing ca-
pacities of SCIN-B and SCIN-C. Opsonization of   S. aureus   
in the presence of SCIN-B or SCIN-C resulted in increased 
amounts of bacterium-bound C2a and Bb, indicating that 
these molecules stabilize C3 convertases (  Fig. 3, G and H  ). 
Collectively, these data show that SCIN-B and SCIN-C in-
hibit complement by stabilization of C3 convertases, which is 
similar to the inhibitory mechanism of SCIN. 
  Complement inhibitory properties of Efb-C and Ecb 
  The pathway specifi  city of Efb-C and Ecb was also analyzed 
by ELISA. At the level of C3b deposition, we found that 
Efb-C and Ecb block the AP but not the CP and LP (  Fig. 4, 
A  –  C  ).   However, C5b-9 formation was eff  ectively blocked 
deposition, and phagocytosis. ORF-D is not a complement 
inhibitor, and its function remains unknown. In contrast to 
SCIN molecules, Efb-C and Ecb do not inhibit phagocytosis 
but strongly interfere with C5a production. 
  SCIN-B and SCIN-C function similar to SCIN 
  To gain more insight into the complement inhibitory mech-
anisms of SCIN-B and SCIN-C, we determined their regu-
latory impact on the diff  erent pathways individually (  36, 37  ). 
ELISA experiments showed that SCIN-B and SCIN-C share 
pathway specifi  city with SCIN (  Fig. 3  ).   Both at the level of 
C3b and C5b-9 formation, SCIN-B and SCIN-C inhibit the 
CP and LP by 50% (  Fig. 3, A, B, D, and E  ), and the AP by 
100% (  Fig. 3, C and F  ). Of note, SCIN-B appears less potent 
in blocking CP and LP activation at the level of C3b (  Fig. 3, 
A and B  ). Like SCIN, SCIN-B and SCIN-C did not block 
  Figure 3.     SCIN-B and SCIN-C function similar to SCIN. ELISA experiments showing that SCIN (     ), SCIN-B (  •  ), and SCIN-C (     ) inhibit C3b deposi-
tion after CP (5% serum; A), LP (5% serum; B), and AP activation (30% serum; C). SCIN, SCIN-B, and SCIN-C also prevent C5b-9 deposition during CP 
(5% serum; D), LP (5% serum; E), and AP activation (30% serum; F). ORF-D (     ) cannot inhibit C3b or C5b-9 deposition in ELISA. Data shown in A  –  F represent 
the mean       SE of three separate experiments. (G and H) SCIN, SCIN-B, and SCIN-C enhance convertase stability during opsonization of   S. aureus   in  20% 
human serum. Opsonization was performed for 0, 2, 10, and 30 min. Surface-bound convertases were detected by immunoblotting using anti-C2 (G) or 
anti-fB (H) antibodies. Blots represent three separate experiments.     JEM VOL. 204, October 1, 2007 
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However, Efb-C and Ecb are potent inhibitors of C5b-9 for-
mation in all complement pathways. 
  Efb-C and Ecb act on the bacterial surface 
  To assess whether Efb-C and Ecb act on the bacterial surface, 
we studied the binding of histidine (His)-tagged Efb-C and 
Ecb to   S. aureus  . The His tag did not infl  uence complement 
inhibitory activities, as was shown by ELISA (unpublished 
data). We clearly observed a serum-dependent binding of 
His  –  Efb-C and His-Ecb to   S. aureus   (  Fig. 5 B  ). The C5-
binding protein of   S. aureus  , His-SSL7 (  19  ), was used as a 
negative control and did not bind to the surface. His-tagged 
Efb-C and Ecb did not bind to bacteria in the presence of 
heat-inactivated serum, demonstrating a complement-de-
pendent interaction. 
by Efb-C and Ecb in all pathways (  Fig. 4, D  –  F  ). In contrast 
to SCIN, Efb-C and Ecb did not enhance convertase stability 
during opsonization of   S. aureus   (  Fig. 4, G and H  ). Because 
Efb-C binds diff  erent C3 molecules via the C3d domain (  29  ), 
we also studied the C3-binding properties of Ecb. Therefore, 
Ecb was coated to microtiter wells and incubated with C3 or 
its fragments. Similar to Efb-C, we found that Ecb specifi  -
cally binds all C3d-containing C3 molecules (C3, C3b, iC3b, 
and C3d), whereas no binding was observed to C3c, which is 
devoid of C3d (  Fig. 5 A  ).   Binding specifi  city was demon-
strated by a lack of binding to C4, C5, fB, and fi  brinogen. 
  Our fi  ndings provide clear evidence that Efb-C and Ecb 
are potent complement inhibitors that act diff  erently than 
SCIN. By binding to C3d-containing molecules, Efb-C and 
Ecb can block C3b deposition in the AP but not in the CP/LP. 
  Figure 4.     Efb-C and Ecb act differently than SCIN. ELISA experiments showing that Efb-C (     ) and Ecb (  Δ  ) do not inhibit C3b deposition after CP 
(5% serum; A) or LP (5% serum; B) activation but strongly block C3b deposition after AP activation (30% serum; C). Efb-C and Ecb strongly prevent C5b-9 
deposition in response to activation of all pathways: CP (5% serum; D), LP (5% serum; E), and AP (30% serum; F). Data shown in A  –  F are the mean       SE 
of three separate experiments. (G and H) Efb-C and Ecb do not enhance convertase stability during opsonization of   S. aureus   in 20% human serum. Opso-
nization was performed for 0, 2, 10, and 30 min. Surface-bound convertases were detected by immunoblotting using anti-C2 (G) or anti-fB (H) antibodies. 
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convertases were incubated with purifi  ed C3 or C5 in the 
presence or absence of Efb-C and Ecb. Formation of C3a and 
C5a was measured by neutrophil calcium mobilization. Efb-C 
and Ecb prevented both C3 cleavage by AP convertases (  Fig. 
7 B  ) and convertases-mediated C5 cleavage (  Fig. 7 C  ). These 
data demonstrate that Efb-C and Ecb prevent convertase cleav-
age of C3 and C5. 
  Efb-C and Ecb inhibit complement in various species 
  The species specifi  city of SCIN-B, SCIN-C, Efb-C, and Ecb 
was determined in an AP-mediated hemolytic assay in which 
MAC-dependent killing of rabbit erythrocytes is used as a 
readout for complement activity. As demonstrated for SCIN, 
SCIN-B and SCIN-C, strongly inhibited AP-mediated he-
molysis in human serum (  Fig. 8 A  ), whereas no inhibition was 
observed in mice (  Fig. 8 B  ) and all other tested species (not 
depicted).   In contrast, we found that Efb-C and Ecb not only 
blocked complement activation in humans but also in mouse 
(  Fig. 8, A and B  ), rat, cow, sheep, goat, guinea pig, and dog 
serum. The fact that Ecb strongly blocks AP activation in mice 
allowed us for the fi  rst time to determine the complement in-
hibitory properties of an   S. aureus    –  derived complement inhibitor 
in vivo. 
  Efb-C and Ecb specifi  cally block 
C3b-containing convertases 
  Our fi  nding that Efb and Ecb act on the bacterial surface 
prompted us to study their regulatory impact on C3 and C5 
convertases. Therefore,   S. aureus   was incubated with human 
serum and the proteolytic activity of C3 convertases was tested 
by measuring C3b deposition, whereas C5 convertase activity 
was monitored by testing C5a release in supernatants using 
neutrophil calcium mobilization assays (  Fig. 6  ).   To exclusively 
assess CP and LP convertases, incubations were performed in 
fD-defi  cient serum. AP convertases were analyzed in the pres-
ence of Mg-EGTA to chelate calcium ions needed for the CP 
and LP (  22  ). We found no inhibition of C3b deposition in the 
presence of Efb-C and Ecb after CP or LP activation (  Fig. 6 A  ). 
In contrast, C5a production was strongly inhibited in re-
sponse to CP or LP activation (  Fig. 6 C  ). Importantly, Efb-C 
and Ecb blocked C3b deposition and C5a-mediated calcium 
mobilization after AP activation (  Fig. 6, B and D  ). Collec-
tively, we demonstrate that Efb-C and Ecb do not aff  ect the 
CP/LP convertase C4b2a but specifi  cally block C3b-containing 
convertases, i.e., the AP C3 convertase (C3bBb) and the C5 
convertases of CP/LP (C4b2aC3b) and AP (C3b  2  Bb). 
  Efb-C and Ecb block convertase activity 
  Because several human convertase inhibitors (e.g., factor H 
[fH] and decay-accelerating factor) promote dissociation of 
convertase complexes, we tested the decay-accelerating prop-
erties of Efb-C and Ecb. Surface-bound AP convertases, cre-
ated by incubating C3b-coated bacteria with fB, fD, and 
properdin (  38  ), were incubated with Efb-C, Ecb, and fH for 
30 min at 37  °  C. Unlike fH, Efb-C and Ecb could not promote 
dissociation of Bb, indicating they do not act as decay-acceler-
ating molecules (  Fig. 7 A  ).   To investigate whether Efb-C and 
Ecb aff  ect substrate cleavage by convertases, zymosan-bound 
  Figure 5.     Complement-binding properties of Efb-C and Ecb. 
(A) Ecb binds the C3d domain of C3 (fragments). 5   μ  g/ml Ecb was coated to 
ELISA plates, and subsequent binding of C3 (     ), iC3b (  Δ  ), C3b (     ), C3c (  •  ), 
and C3d (     ) was determined. Ecb exclusively binds C3d-containing C3 
molecules. (B) Efb-C (     ) and Ecb (  Δ  ) bind to   S. aureus   in a serum-dependent 
manner. 10      g/ml of His-tagged Efb-C and Ecb were incubated with 
  S. aureus   and human serum for 30 min at 37 C, and binding was detected 
using anti-His antibodies and fl  ow cytometry. His-tagged SSL7 served as 
a negative control. Graphs show one representative fi  gure out of three 
separate experiments. Mean fl  , mean fl   uorescence.   
  Figure 6.     Efb-C and Ecb act on C3b-containing convertases. Efb-C 
and Ecb specifi  cally block C3b-containing convertases.   S. aureus   was 
incubated with 10% fD-depleted serum (to measure CP and LP activation) 
or 10% human serum in the presence of Mg-EGTA (to measure AP activa-
tion). Complement activation was measured at the level of C3b deposition 
by fl  ow cytometry using anti-C3 antibodies (A and B) or at the level of 
C5a production by calcium mobilization (C and D). Efb-C (     ) and Ecb (    ) 
do not prevent C3b deposition by the CP/LP (A) but inhibit C3b deposition 
by the AP (B). Formation of C5a was blocked in response to CP and LP 
activation (C), as well as AP activation (D). Data shown represent the 
mean       SE of three separate experiments. Mean fl  , mean fl   uorescence.   JEM VOL. 204, October 1, 2007 
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soluble IC disease, the Arthus reaction, IC activation of local 
resident cells results in edema, hemorrhage, and neutrophil 
infi  ltration. We used the well-established reverse passive Arthus 
reaction peritonitis model to assess the in vivo activity of Ecb 
(  39  ). In the absence of inhibitory protein, neutrophils accu-
mulate in the peritoneal cavity within 6 h after IC challenge 
(  Fig. 9 A  ).   i.p. and i.v. injection of Ecb before IC challenge 
resulted in complete inhibition of neutrophil migration. In-
jection of Ecb alone did not induce IC peritonitis. The anti-
infl  ammatory eff  ect of Ecb is similar to deletion of the C5aR 
or IgG Fc receptor (  39  ). 
  To prove that Ecb also prevents C5a generation and C5a-
mediated neutrophil migration in mice, zymosan was prein-
cubated with EGTA plasma from C5-suffi   cient C57BL/6 
mice and C5-defi  cient A/J mice to activate the AP. The plasma 
was then assessed for its ability to induce migration of BM-
derived mouse neutrophils. Strong neutrophil migration oc-
curred in response to C5-suffi   cient but not C5-defi  cient 
plasma (  Fig. 9 B  ), demonstrating that neutrophil migration 
depends on AP-activated C5a. C5-suffi   cient plasma that had 
been activated in the presence of Ecb was strongly impaired in 
its capacity to induce neutrophil migration (  Fig. 9 B  ). Collec-
tively, these data show that Ecb inhibits the AP-induced acti-
vation of C5 necessary to induce neutrophil migration both 
in vitro and in vivo. 
  Ecb strongly blocks immune complex (IC)  –  mediated 
infl  ammation in mice 
  ICs are critical for the pathogenesis of several autoimmune 
diseases, including systemic lupus erythematosus, rheumatoid 
arthritis, and glomerulonephritis. In addition to the inter-
action with IgG Fc receptors, ICs also activate the CP and 
AP and attract various immune cells through the ligation of 
complement receptors. In the classical experimental model of 
  Figure 7.     Efb-C and Ecb inhibit C3 and C5 cleavage by convertases. 
(A) Efb-C and Ecb do not promote decay of convertases. AP con  vertases 
were created on the bacterial surface using purified components. 
Subsequent incubation with inhibitors showed that Efb-C and Ecb do not 
dissociate convertases like fH. Surface-bound convertases were detected 
using anti-Bb antibodies and fl  ow cytometry. (B and C) Efb-C and Ecb 
inhibit convertase activity. Zymosan-bound convertases were incubated 
with purifi  ed C3 or C5, and generated C3a or C5a was measured in a 
neutrophil calcium mobilization assay. (B) Efb-C and Ecb inhibit C3 cleavage 
by AP convertases. (C) Efb-C and Ecb inhibit C5 cleavage by convertases. 
Data shown represent the mean       SE of three separate experiments. 
Mean fl  , mean fl   uorescence.   
  Figure 8.     Efb-C and Ecb are not human specifi  c. (A) SCIN-B, SCIN-C, 
Efb-C, and Ecb inhibit AP-mediated hemolysis of rabbit red blood cells 
in human serum. SCIN-B (     ) and SCIN-C (     ) completely block hemolysis 
at high serum concentrations. Efb-C (     ) and Ecb (  Δ  ) also inhibit AP-
mediated hemolysis but are less effective than SCIN-B or SCIN-C (all inhib-
itors at 10  μ  g/ml). (B) Efb-C and Ecb inhibit AP-mediated hemolysis in 
mouse serum. Addition of 10   μ  g/ml Efb-C (     ) or Ecb (  Δ  ) results in strong 
inhibition of MAC formation in mouse serum, whereas SCIN-B (    )  and 
SCIN-C (     ) had no effect. Graphs show one representative fi  gure out of 
three separate experiments.     2468 CONVERTASE INHIBITION BY   STAPHYLOCOCCUS AUREUS   | Jongerius et al.
is the subject for further studies. The immune-modulating 
properties of SSL12  –  14 are very likely, because the SSLs, 
structural homologues of superantigens that lack superantigen 
activity, are believed to modulate various innate immune 
functions (  31  ): SSL5 binds P-selectin glycoprotein ligand 1 to 
inhibit neutrophil rolling on epithelial cells (  40  ), and SSL7 
binds IgA and C5 and blocks IgA-FcR and C5 activation. 
(  19  ). In contrast to the bacteriophage-located IEC-1, the 
borders and nature of IEC-2 are less clear. Because IEC-2 
contains mobile elements and bacteriophage remnants, we 
believe horizontal gene transfer has played a role in its devel-
opment. In sharp contrast to IEC-1, IEC-2 is not human 
specifi  c, as indicated by its presence in the bovine   S. aureus   
strain RF122 and the cross-reactivity of Efb and Ecb in sev-
eral animal species. 
  In this paper, we highlight two diff  erent mechanisms used 
by   S. aureus   to regulate complement convertases. The SCIN 
molecules (SCIN, SCIN-B, and SCIN-C) specifi  cally block 
C3 convertases (C4b2a and C3bBb) to prevent C3b/iC3b 
deposition, phagocytosis, and C5a generation. SCIN does not 
directly bind C3b but exclusively binds the activated C3 con-
vertase, causing both stabilization and inactivation of this 
complex (  22  ). Furthermore,   S. aureus   secretes C3d-binding 
molecules (Efb and Ecb) that specifi  cally inactivate C3b-
containing convertases, i.e., the AP C3 convertase (C3bBb) and 
the C5 convertases of CP/LP (C4b2aC3b) and AP (C3b  2  Bb). 
Because inhibition of the AP C3 convertase is not suffi   cient 
to block opsonization and phagocytosis in whole-serum as-
says, we believe that the major bacterial defense functions of 
Efb-C and Ecb are to block C5a production by C5 conver-
tases and to down-regulate neutrophil responses. Because a 
previous report has indicated that Efb-C induces a conforma-
tional change in both C3b and C3, it was suggested that Efb-C 
blocks formation of a functional opsonin (  41  ). However, our 
data indicate that Efb-C and Ecb do not directly block C3 
cleavage and opsonin formation, because C3b deposition by 
the CP/LP was not aff  ected at physiological inhibitor con-
centrations. Furthermore, the complement-dependent bind-
ing to bacteria demonstrates that Efb-C and Ecb act on the 
bacterial surface rather than in fl  uid phase. The fi  nding that 
Efb-C and Ecb inhibit the CP/LP C5 convertase (C4b2aC3b) 
but not the C3 convertase (C4b2a) strongly suggests that they 
bind convertases via C3b. The conformational change in 
C3b (  41  ) likely aff  ects the activity of the protease complex. 
We observed that Efb-C and Ecb do not aff  ect the stability of 
the complex but block cleavage of the substrate (C3 or C5). 
This, along with the fact that C3b molecules within C5 con-
vertases provide the additional binding sites for C5 (  15, 17, 18, 
42  –  44  ), suggests that Efb-C and Ecb block substrate binding 
via C3b. 
  The identifi  cation of four novel convertase inhibitors in 
  S. aureus   illustrates the crucial role of convertase modulation for 
bacterial survival. It is remarkable that a single bacterium pro-
duces fi  ve diff  erent convertase inhibitors, stressing the impor-
tance of appropriate complement activation for   S. aureus   killing. 
In concert with several additional complement modulators (  45  ), 
    DISCUSSION   
  The human pathogen   S. aureus   successfully evades innate im-
mune defenses by secretion of numerous small molecules that 
inhibit critical steps of the immune response. In this study, 
we identify SCIN-B, SCIN-C, Efb, and Ecb as four new 
staphylococcal complement modulators that block convertases, 
the central protease complexes of the complement cascade. 
Direct convertase modulators are specifi  c for   S. aureus   and 
provide a very eff  ective way of blocking complement. This 
paper shows that convertase inhibition is a very powerful 
mechanism to block infl  ammatory reactions initiated by com-
plement both in vitro and in vivo. 
  The fi  rst IEC in   S. aureus   (IEC-1) encodes four important 
immune modulators, including SCIN and CHIPS (  25  ). With 
the discovery of SCIN and CHIPS homologues, we are now 
confronted with the second IEC in   S. aureus  . Six molecules 
on IEC-2 (FLIPr [  26  ], FLIPr-like [unpublished data], SCIN-B, 
SCIN-C, Efb, and Ecb) are now known to have immune 
evasive properties. The role of the other molecules on IEC-2 
  Figure 9.     Ecb completely blocks IC-induced neutrophil infl  ux 
in vivo. (A) In vivo complement inhibition by Ecb was tested in the reverse 
passive Arthus reaction peritonitis model. Neutrophils accumulate in the 
peritoneal cavity within 6 h after IC challenge. i.p. and i.v. injection of Ecb 
before IC challenge resulted in complete inhibition of neutrophil migration. 
Injection of Ecb alone did not induce IC peritonitis. P       0.001  by 
analysis of variance (  n     10 mice per group). (B) Ecb completely blocks 
C5a-dependent migration of BM-derived mouse neutrophils in vitro. 
Preincubation of zymosan with C5-suffi  cient (     ) but not C5-defi  cient 
plasma (     ) results in neutrophil migration. In the presence of 50     g/ml 
Ecb, C5a production in C5-suffi  cient plasma was blocked (     ). Data shown 
represent the mean   SE of three separate experiments.     JEM VOL. 204, October 1, 2007 
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previously described (  23  ). C5a specifi  city of this assay was verifi  ed by pre-
incubation of neutrophils with the C5a receptor antagonist CHIPS    −  30   (  21  ). 
To analyze CD11b and CD62L expression, neutrophils were placed on ice 
for 10 min, after which expression of CD11b and CD62 was measured using 
PE-conjugated anti  –  human CD62L (BD Biosciences) and FITC-labeled 
anti  –  human CD11b (  48  ) and fl  ow cytometry. C3b deposition was performed 
by incubation of   S. aureus   with 10% human sera in HBS  2    (Hepes-buff  ered 
saline, 20 mM Hepes, 140 mM NaCl, 5 mM CaCl  2  , and 2.5 mM MgCl  2  ), 
after which surface-bound C3b was detected with FITC-conjugated (Fab     )  2   
anti  –  human C3 (Protos Immunoresearch). Exclusive activation of the CP/LP 
was performed in fD-defi  cient serum (  22  ). The AP was analyzed in serum 
supplemented with Mg-EGTA. Before calcium mobilization, Mg-EGTA  –
  containing supernatants were supplemented with 12 mM CaCl  2  . To analyze 
binding,   S. aureus   was incubated with 10      g/ml His  –  Efb-C or His-Ecb and 
human sera for 30 min at 37 C. His-tagged proteins were detected using 
mouse anti  –  His tag antibodies (QIAGEN), FITC-labeled goat anti  –  mouse 
IgG (DakoCytomation), and fl  ow cytometry. 
  ELISAs.     Complement ELISAs were performed as previously described (  36, 37  ), 
with minor modifi  cations. Deposited C3b and C5b-9 were detected using 
anti-C3c WM1 (American Type Culture Collection) (  48  ) and anti  –  C5b-9 
(Abcam) antibodies, respectively, followed by peroxidase (PO)-conjugated 
goat anti  –  mouse IgG (Southern Biotechnology Associates, Inc.). Antibody 
distribution in humans was determined as previously described (  20  ). To 
study binding of complement proteins by ELISA (  20, 23  ), inhibitor-coated 
wells (10      g/ml) were incubated with human C5, C4, fB, fH C3, C3b, C3d 
(all obtained from Calbiochem), or C3c (provided by B. Janssen, Utrecht 
University, Utrecht, Netherlands). Binding of complement proteins was 
  detected using monoclonal antibodies against human C3c (WM1), C3d 
(Quidel Corp.), C5/C5b (HyCult Biotechnology), Bb (Quidel Corp.), fH 
(Quidel Corp.), or C4d (Quidel Corp.) and secondary PO-conjugated anti  –
  mouse antibodies. 
  Convertase analyses.     Detection of bacterium-bound convertases after op-
sonization was performed as previously described for SCIN (  22  ). To prepare 
C3b-covered bacteria,   S. aureus   was incubated with 20% human sera for 
30 min in HBS  2   , followed by a 30-min incubation in PBS at 37  °  C to dissociate 
surface-bound C2a/Bb (  22  ). To create purifi  ed convertases on the bacterial 
surface, C3b-covered bacteria were incubated with 40      g/ml fB, 1      g/ml fD, 
and 4      g/ml properdin (all obtained from Calbiochem) for 30 min at 37  °  C in 
HBS  2   . To analyze stability, convertases were incubated with 20   μ  g/ml Efb-C, 
Ecb, or fH (Calbiochem) for 30 min at 37  °  C in HBS  2   . Surface-bound Bb 
was detected by fl  ow cytometry (  22  ). Cleavage of C3 and C5 by surface-
bound convertases was studied on zymosan. Convertases were created by in-
cubating zymosan particles with serum in PBS supplemented with 2 mM 
NiCl  2   (to increase convertase stability) for 30 min at 37  °  C. Washed zymosan 
particles were subsequently incubated with Efb-C, 10      g/ml Ecb, or PBS for 
5 min at 37  °  C before 4      g/ml human C5 or C3 (Calbiochem) was added for 
1 h at 37  °  C. For C3 activation, zymosan was opsonized in C2-defi  cient 
serum (Sigma-Aldrich) to exclusively form AP convertases. C5 cleavage was 
assessed using particles opsonized in normal serum. Formation of C5a or C3a 
was measured by analyzing supernatants in a calcium mobilization assay. AP 
hemolytic assays were performed as previously described (  22  ). 
  Preparation of mouse EGTA plasma.     Blood was drawn from C57BL6 
(  n     10) and A/J mice (  n     10) by cardiac puncture in syringes containing 
0.2 M EGTA (Sigma-Aldrich) as an anticoagulant. Cells were pelleted by 
centrifugation in a swing-out rotor at 1,400   g   for 10 min at 4°C. 
  Zymosan-induced complement activation.     2.5 ml EGTA plasma from 
either C57BL6 or A/J mice was heated to 37  °  C for 30 min in the presence 
or the absence of 50      g/ml Ecb. The plasma was then treated with 1.335 mg 
PL-2-mercaptomethyl-3-guanidinoethylthio-propanoic acid (Calbiochem), 
47      l of 4 M 6-aminohexanoic acid (Fluka), 1 ml of washed zymosan A, and 
187.5      l of 0.2 M MgCl  2   at 37  °  C for 1 h to activate the AP of complement 
  S. aureus   contains an enormous arsenal of molecules that can 
block the complement cascade at diff  erent steps. These syner-
gistic inhibitory pathways help the bacterium to prevent C5a-
mediated neutrophil responses and/or phagocytosis. The fact 
that all staphylococcal complement modulators are produced 
in vivo suggests that they are benefi  cial for bacterial survival in 
the human host. The redundancy of this system is reminiscent 
of the mechanisms used by herpes viruses to escape antigen 
processing. Similar to   S. aureus  , herpes viruses evade host-
mediated immunity by the blockade of diff  erent steps of the 
immune response, i.e., inhibition of diff  erent molecules critical 
for antigen processing (  46, 47  ). 
  The identifi  cation of two nonhuman specifi  c comple-
ment modulators allows us for the fi  rst time to study the role 
of complement modulation in bacterial pathogenesis in vivo. 
Ecb strongly prevented the development of neutrophil-
  mediated infl  ammation in a mouse model of IC-induced 
peritonitis. Our data suggest that the convertase-inhibitory 
molecules evolved in   S. aureus   are promising drug candidates 
for antiinfl  ammatory therapy, though the occurrence of pre-
existing antibodies precludes their use in humans in their 
original form (  45  ). However, as the active sites of SCIN and 
Efb-C comprise only minor parts of the molecule (  25, 41  ), 
these molecules are promising lead compounds for the devel-
opment of small nonimmunogenic complement inhibitors. 
The strong antiinfl  ammatory eff  ect of Ecb in vivo illustrates 
the therapeutic potential of such molecules in severe acute 
infl  ammatory disorders. 
  MATERIALS AND METHODS 
  Recombinant production of   S. aureus   proteins.     To enable protein 
  expression with a cleavable N-terminal His tag, genes (without signal 
  sequences) were cloned into the pRSETB vector (Invitrogen). Primers are 
listed in Table S1 (available at http://www.jem.org/cgi/content/full/
jem.20070818/DC1). Cloning of SCIN homologues was performed as pre-
viously described (  22  ). Efb, Efb-C, and Ecb were cloned by overlap exten-
sion PCR (  24  ). In the fi  rst PCR reaction, a small region of pRSETB was 
amplifi  ed using XbaI forward and enterokinase (EK) cleavage site reverse 
(EK-reverse; Table S1) primers. The EK-reverse primers contain a 3      over-
hang on the Efb genes. In a second PCR,   efb   and   ecb   were amplifi  ed from 
chromosomal   S. aureus   DNA using EK-forward primers (to provide a 5      
overhang on the EK site) and EcoRI-reverse primers (providing a 3      EcoRI 
cleavage site). Both PCR products were mixed and amplifi  ed in a third PCR 
reaction using XbaI forward and EcoRI-reverse. PCR products and pR-
SETB were digested with XbaI and EcoRI before ligation. Transformation 
and expression were performed as previously described (  21, 22  ). Proteins 
were expressed in   E. coli   and purifi  ed from bacterial lysates by nickel affi   nity 
chromatography (  21  ). The His tag was removed by EK cleavage and sepa-
rated by a second column passage. The His tag of Efb was not removed be-
cause EK cleavage resulted in unwanted proteolysis. PCR analyses of clinical 
  S. aureus   strains was performed as previously described (  25  ) using the pR-
SETB cloning primers for   orf-d  ,   efb  , and   ecb   and specifi  cally designed primers 
for   scb   and   scc   (designated with   “  I  ”   in Table S1). 
  Phagocytosis and complement activation on   S. aureus  .     Laboratory 
strain   S. aureus   Wood was used for phagocytosis and bacterial complement 
assays. Phagocytosis was performed using FITC-labeled   S. aureus  , human 
sera, and freshly isolated human neutrophils (  22, 48  ). For C5a analyses, heat-
killed   S. aureus   (to prevent formyl-Met-Leu-Phe production) was incubated 
with human sera in RPMI 1640 medium for 30 min at 37 C. Subsequently, 
collected supernatants were tested for neutrophil calcium mobilization, as 2470 CONVERTASE INHIBITION BY   STAPHYLOCOCCUS AUREUS   | Jongerius et al.
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  Staphylococcus aureus   are located on beta-hemolysin-converting bacterio-
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and to block serum carboxypeptidase N. The activated plasma was centri-
fuged at 20,000   g   for 1 h at 4  °  C to precipitate large plasma proteins. The 
supernatant, containing the anaphylatoxins, was stored at   −  80  °  C. 
  Neutrophil chemotaxis.     To obtain BM-derived neutrophils, femurs, 
  tibias, and humeri of BALB/c mice were fl  ushed with sterile PBS. The migra-
tion of BM-derived neutrophils was determined using a 48-well micro-
chemotaxis chamber (Neuro Probe) with polycarbonate fi  lters (pore size, 3      m). 
Twofold serial dilutions (1:2 to 1:64) of Ecb-treated and untreated zymosan-
activated plasma from C57BL6 and A/J mice were generated using 2% BSA-
GBSS (Sigma-Aldrich) as diluent. 30      l of the diluted plasma was added to 
the lower well to act as a chemoattractant to 50      l of neutrophils (10  7   neu-
trophils per milliliter suspended in 2% BSA-GBSS buff  er), which were added 
to the upper wells. Cells were allowed to migrate for 30 min at 37  °  C. Mem-
branes were separated, fi  xed with methanol, and stained with Diff  -Quick 
(BaxterDade). The numbers of neutrophils per square micrometer migrating 
beyond the lower surface of the membrane were determined microscopically 
(     20 high power fi  elds, 32      magnifi  cation). 
  Peritoneal Arthus reaction.     BALB/c mice were i.v. injected with 100      l 
of OVA (20 mg/kg of body weight; Sigma-Aldrich), immediately followed 
by i.p. injection of 200      l of rabbit anti-OVA IgG (800      g per mouse; MP 
Biomedicals) in sterile PBS. In inhibition experiments, 100      l Ecb was ad-
ministered i.v. and i.p. (600      g/ml) 30 min before initiation of the Arthus 
reaction. Further, Ecb was administered i.v. and i.p. using the same concen-
trations in the absence of the Arthus reaction (as a control). Mice of diff  erent 
treatment groups were killed 6 h after onset of the peritoneal Arthus reaction. 
The peritoneal cavity was lavaged with 6 ml of ice-cold PBS/0.1% BSA. 
Peritoneal cells were washed once with PBS, and the cell number was ad-
justed to 5       10  5   cells per milliliter. 50      l of this cell suspension was used 
to prepare cytospin slides, which were stained with Diff  Quick. Neutrophil 
numbers per square millimeter were calculated from      20 diff  erent micros-
copic fi  elds. Animal care was provided in accordance with National Insti-
tutes of Health guidelines. Animal studies were approved by either the 
Bezirksregierung Hannover or the Cincinnati Children  ’  s Hospital Medical 
Center institutional animal care and use committee. 
  Accession numbers.     SCIN-B (  NP_374275  ,   NP_371683  ,   YP_186032  ,   YP_
493754  ,   YP_499659  ,   YP_416506  ,   YP_043217  ,   NP_645858  , and   YP_040544  ), 
SCIN-C ( YP_040544  ), ORF-D ( YP_039686  ), Ecb ( NP_374271  ,  NP_371679  , 
  YP_186027  ,   YP_493750  ,   YP_499654  ,   YP_416502  ,   YP_043213  ,   NP_645854  , 
and  YP_040541  ), and Efb ( NP_374274  ,  NP_371682  ,  YP_186031  ,  YP_493753  , 
  YP_499658  ,   YP_416505  ,   YP_043216  ,   NP_645857  , and   YP_040543  ) are 
available from GenBank/EMBL/DDBJ under the accession numbers listed. 
  Online supplemental material.     Table S1 lists the primers used in this 
study. Fig. S1 A represents sequence alignments of SCIN, SCIN-B, SCIN-C, 
and ORF-D; Fig. S1 B represents sequence alignments of Efb, Efb-C, and Ecb. 
Online supplemental material is available at http://www.jem.org/cgi/content/
full/jem.20070818/DC1. 
  This work was supported by grants from the Netherlands Genomics Initiative  –
  Horizon (050-71-028), the Netherlands Organisation for Scientifi  c Research 
(NWO)  –  TOP (9120.6020), NWO-VENI (916-76-037), and the National Institutes of 
Health (R01-AI59306 to J. Kohl). 
  The authors have no confl  icting fi  nancial interests. 
Submitted:   23 April 2007 
Accepted:   29 August 2007 
  REFERENCES 
       1  .   Neth  ,   O.  ,   D.L.     Jack  ,   M.     Johnson  ,   N.J.     Klein  , and   M.W.     Turner  . 
  2002  .   Enhancement of complement activation and opsonophagocy-
tosis by complexes of mannose-binding lectin with mannose-binding 
lectin-  associated serine protease after binding to   Staphylococcus aureus  .   
    J. Immunol.       169  :  4430    –    4436  .   JEM VOL. 204, October 1, 2007 
ARTICLE
2471
        26  .   Prat  ,   C.  ,   J.     Bestebroer  ,   C.J.     de Haas  ,   J.A.     van Strijp  , and   K.P.     van Kessel  . 
  2006  .   A new staphylococcal anti-infl  ammatory protein that antagonizes 
the formyl peptide receptor-like 1.       J. Immunol.       177  :  8017    –    8026  .   
        27  .   Boden  ,   M.K.  , and   J.I.     Flock  .   1992  .   Evidence for three diff  erent fi  brinogen-
binding proteins with unique properties from   Staphylococcus aureus   strain 
Newman.       Microb. Pathog.       12  :  289    –    298  .   
        28  .   Boden  ,   M.K.  , and   J.I.     Flock  .   1994  .   Cloning and characterization of 
a gene for a 19 kDa fi  brinogen-binding protein from   Staphylococcus aureus  .   
    Mol. Microbiol.       12  :  599    –    606  .   
        29  .   Lee  ,   L.Y.  ,   X.     Liang  ,   M.     Hook  , and   E.L.     Brown  .   2004  .   Identifi  cation 
and characterization of the C3 binding domain of the   Staphylococcus 
aureus   extracellular fi   brinogen-binding protein (Efb).       J. Biol. Chem.     
  279  :  50710    –    50716  .   
        30  .   Lee  ,   L.Y.  ,   M.     Hook  ,   D.     Haviland  ,   R.A.     Wetsel  ,   E.O.     Yonter  ,   P.   
  Syribeys  ,   J.     Vernachio  , and   E.L.     Brown  .   2004  .   Inhibition of comple-
ment activation by a secreted   Staphylococcus aureus   protein.       J. Infect. Dis.     
  190  :  571    –    579  .   
        31  .   Fitzgerald  ,   J.R.  ,   S.D.     Reid  ,   E.     Ruotsalainen  ,   T.J.     Tripp  ,   M.     Liu  ,   R.   
  Cole  ,   P.     Kuusela  ,   P.M.     Schlievert  ,   A.     Jarvinen  , and   J.M.     Musser  .   2003  . 
  Genome diversifi  cation in   Staphylococcus aureus  : Molecular evolution of 
a highly variable chromosomal region encoding the Staphylococcal exotoxin-
like family of proteins.       Infect. Immun.       71  :  2827    –    2838  .   
        32  .   Frost  ,   L.S.  ,   R.     Leplae  ,   A.O.     Summers  , and   A.     Toussaint  .   2005  .   Mobile 
genetic elements: the agents of open source evolution.       Nat. Rev. Microbiol.     
  3  :  722    –    732  .   
        33  .   Coenjaerts  ,   F.E.  ,   A.M.     Walenkamp  ,   P.N.     Mwinzi  ,   J.     Scharringa  ,   H.A.   
  Dekker  ,   J.A.     van Strijp  ,   R.     Cherniak  , and   A.I.     Hoepelman  .   2001  . 
  Potent inhibition of neutrophil migration by cryptococcal mannoprotein-4-
induced desensitization.       J. Immunol.       167  :  3988    –    3995  .   
      34  .   Lutz  ,   H.U.  , and   E.     Jelezarova  .   2006  .   Complement amplifi  cation revisited.   
    Mol. Immunol.       43  :  2    –    12  .   
        35  .   Mollnes  ,   T.E.  ,   O.L.     Brekke  ,   M.     Fung  ,   H.     Fure  ,   D.     Christiansen  ,   G.   
  Bergseth  ,   V.     Videm  ,   K.T.     Lappegard  ,   J.     Kohl  , and   J.D.     Lambris  .   2002  . 
  Essential role of the C5a receptor in   E. coli  -induced oxidative burst and 
phagocytosis revealed by a novel lepirudin-based human whole blood 
model of infl  ammation.       Blood    .   100  :  1869    –    1877  .   
        36  .   Roos  ,   A.  ,   L.H.     Bouwman  ,   J.     Munoz  ,   T.     Zuiverloon  ,   M.C.     Faber-Krol  , 
  F.C.     Fallaux-van den Houten  ,   N.     Klar-Mohamad  ,   C.E.     Hack  ,   M.G.   
  Tilanus  , and   M.R.     Daha  .   2003  .   Functional characterization of the lectin 
pathway of complement in human serum.       Mol. Immunol.       39  :  655    –    668  .   
        37  .   Seelen  ,   M.A.  ,   A.     Roos  ,   J.     Wieslander  ,   T.E.     Mollnes  ,   A.G.     Sjoholm  , 
  R.     Wurzner  ,   M.     Loos  ,   F.     Tedesco  ,   R.B.     Sim  ,   P.     Garred  ,   et al  .   2005  . 
  Functional analysis of the classical, alternative, and MBL pathways of the 
complement system: standardization and validation of a simple ELISA.   
    J. Immunol. Methods    .   296  :  187    –    198  .   
      38  .   Hourcade  ,  D.E.    2006  .  The role of properdin in the assembly of the alternative 
pathway C3 convertases of complement.       J. Biol. Chem.       281  :  2128    –    2132  .   
        39  .   Godau  ,   J.  ,   T.     Heller  ,   H.     Hawlisch  ,   M.     Trappe  ,   E.     Howells  ,   J.     Best  , 
  J.     Zwirner  ,   J.S.     Verbeek  ,   P.M.     Hogarth  ,   C.     Gerard  ,   et al  .   2004  .   C5a 
initiates the infl  ammatory cascade in immune complex peritonitis.   
    J. Immunol.       173  :  3437    –    3445  .   
        40  .   Bestebroer  ,   J.  ,   M.J.     Poppelier  ,   L.H.     Ulfman  ,   P.J.     Lenting  ,   C.V.     Denis  , 
  K.P.     van Kessel  ,   J.A.     van Strijp  , and   C.J.     de Haas  .   2007  .   Staphylococcal 
superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated 
neutrophil rolling.       Blood    .   109  :  2936    –    2943  .   
        41  .   Hammel  ,   M.  ,   G.     Sfyroera  ,   D.     Ricklin  ,   P.     Magotti  ,   J.D.     Lambris  , and 
  B.V.     Geisbrecht  .   2007  .   A structural basis for complement inhibition by 
  Staphylococcus aureus  .       Nat. Immunol.       8  :  430    –    437  .   
        42  .   Rawal  ,  N.  , and  M.K.    Pangburn  .  2000  .  Functional role of the noncatalytic 
subunit of complement C5 convertase.       J. Immunol.       164  :  1379    –    1385  .   
        43  .   Rawal  ,   N.  , and   M.K.     Pangburn  .   2003  .   Formation of high affi   nity 
C5 convertase of the classical pathway of complement.       J. Biol. Chem.     
  278  :  38476    –    38483  .   
        44  .   Rawal  ,   N.  , and   M.K.     Pangburn  .   2007  .   Role of the C3b-binding site on 
C4b-binding protein in regulating classical pathway C5 convertase.       Mol. 
Immunol.       44  :  1105    –    1114  .   
      45  .   Rooijakkers  ,   S.H.  , and   J.A.     van Strijp  .   2006  .   Bacterial complement evasion.   
    Mol. Immunol.       44  :  23    –    32  .   
        46  .   Novak  ,   N.  , and   W.M.     Peng  .   2005  .   Dancing with the enemy: the inter-
play of herpes simplex virus with dendritic cells.       Clin. Exp. Immunol.     
  142  :  405    –    410  .   
        47  .   Ploegh  ,   H.L.     1998  .   Viral strategies of immune evasion.       Science    .   280  :
  248    –    253  .   
        48  .   Veldkamp  ,   K.E.  ,   K.P.     van Kessel  ,   J.     Verhoef  , and   J.A.     van Strijp  . 
  1997  .   Staphylococcal culture supernates stimulate human phagocytes.   
    Infl  ammation    .   21  :  541    –    551  .                         